Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial.

Abstract

OBJECTIVES:

To study the efficacy of rescue treatment strategies and outcomes in patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) not achieving remission with first-line induction with corticosteroids (CS) and intravenous cyclophosphamide (CYC).

METHODS:

159 eligible patients in the Wegener's Granulomatosis-Entretien (WEGENT) trial newly diagnosed with systemic or renal WG or MPA with ≥ 1 poor prognosis factors were included in this prospective study. Rescue treatment strategies and outcomes in patients with induction-refractory disease were analysed and patient characteristics at diagnosis were compared with those of induction-responders.

RESULTS:

Most patients (n=126, 79.2%) achieved remission; 1 stopped induction because of allergy and 32 were induction-refractory (24 WG and 8 MPA); 11 died rapidly within a median of 2.5 months, 6 of uncontrolled disease, 1 of an infectious complication and 4 of both. Treatment was discontinued in 1 patient with MPA with end-stage renal disease. Induction was switched to oral CYC in 20 patients, combined with infliximab in 1; 15 (75%) achieved remission or low disease activity state, 3 subsequently died of uncontrolled disease and 2 entered remission using several other agents including biological agents. Alveolar haemorrhage and a creatinine level >200 μmol/l were independently associated with induction-refractory disease. Among patients with induction-refractory disease, massive alveolar haemorrhage was associated with higher mortality.

CONCLUSION:

Switching to oral CYC can be an effective rescue treatment for patients with systemic forms of WG or MPA who fail to achieve remission with first-line CS and intravenous CYC. However, a more rapidly effective regimen remains to be identified for most severely affected patients whose outcomes can be rapidly fatal.

• Authors: Raphaèle Seror, Christian Pagnoux, Marc Ruivard, Isabelle Landru, Denis Wahl, Sophie Rivière, Solveig Aussant, Alfred Mahr, Pascal Cohen, Luc Mouthon, Loïc Guillevin, French Vasculitis Study Group
• Journal: Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 69 Issue 12 Pg. 2125-30 (Dec 2010) ISSN: 1468-2060 [Electronic] England
• PMID: 20643762 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Glucocorticoids
• Immunosuppressive Agents
• Cyclophosphamide

Topics

• Administration, Oral
• Adult
• Aged
• Cyclophosphamide (administration & dosage, therapeutic use)
• Drug Therapy, Combination
• Female
• Glucocorticoids (therapeutic use)
• Granulomatosis with Polyangiitis (drug therapy)
• Humans
• Immunosuppressive Agents (administration & dosage, therapeutic use)
• Infusions, Intravenous
• Male
• Microscopic Polyangiitis (drug therapy)
• Middle Aged
• Prognosis
• Prospective Studies
• Treatment Failure
• Treatment Outcome